Neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) phase II trial - initial oncological outcomes

被引：0
|
作者：
Yang, X. [1 ]
Aslim, E. J. [1 ]
Ngo, N. T. [1 ]
Khor, L. Y. [1 ]
Chong, T. W. [1 ]
Yuen, J. S. P. [1 ]
Tay, K. J. [1 ]
Ho, H. S. S. [1 ]
Lee, L. S. [1 ]
机构：
[1] Singapore Gen Hosp, Singapore, Singapore
来源：
BJU INTERNATIONAL | 2019年 / 123卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
C-10162
引用
收藏
页码：40 / 40
页数：1
相关论文
共 50 条
  • [31] A phase II trial of neoadjuvant docetaxel and estramustine followed by radical prostatectomy or radiation therapy for patients with high-risk prostate cancer
    Goyal, L. K.
    Ramsey, S. N.
    Godley, P.
    Pruthi, R.
    Wallen, E.
    Whang, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S362 - S362
  • [32] Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer
    Dreicer, R
    Magi-Galluzzi, C
    Zhou, M
    Rothaermel, J
    Reuther, A
    Ulchaker, J
    Zippe, C
    Fergany, A
    Klein, EA
    UROLOGY, 2004, 63 (06) : 1138 - 1142
  • [33] Definition of high-risk prostate cancer impacts oncological outcomes after radical prostatectomy
    Knipper, Sophie
    Karakiewicz, Pierre I.
    Heinze, Alexander
    Preisser, Felix
    Steuber, Thomas
    Huland, Hartwig
    Graefen, Markus
    Tilki, Derya
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (04) : 184 - 190
  • [34] Combination approach using neoadjuvant therapy with radical prostatectomy for improving oncological outcomes of high-risk prostate cancer: a narrative review
    Nakane, Keita
    Kawase, Makoto
    Kato, Daiki
    Iinuma, Koji
    Kawase, Kota
    Takeuchi, Shinichi
    Tobisawa, Yuki
    Ito, Takayasu
    Koie, Takuya
    TRANSLATIONAL CANCER RESEARCH, 2024, 13 (07) : 3889 - 3897
  • [35] Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer
    Clark, PE
    Peereboom, DM
    Dreicher, R
    Levin, HS
    Clark, SB
    Klein, EA
    UROLOGY, 2001, 57 (02) : 281 - 285
  • [36] INTERMEDIATE-TERM OUTCOMES OF RADICAL PROSTATECTOMY FOR CLINICALLY HIGH-RISK PROSTATE CANCER
    Kroepfl, Darko
    Roggenbuck, Ulla
    Musch, Michael
    Klevecka, Virgilijus
    JOURNAL OF UROLOGY, 2009, 181 (04): : 718 - 719
  • [37] The role of radical prostatectomy as an initial approach for the treatment of high-risk prostate cancer
    Jaunarena, J. H.
    Villamil, W.
    Martinez, P. F.
    Gueglio, G.
    Giudice, C. R.
    ACTAS UROLOGICAS ESPANOLAS, 2016, 40 (06): : 353 - 360
  • [38] Comparing the Oncological Outcomes of Cryoablation vs. Radical Prostatectomy in Low-Intermediate Risk Localized Prostate Cancer
    Guo, Xiao-xiao
    Liu, Sheng-jie
    Wang, Miao
    Hou, Hui-min
    Wang, Xuan
    Zhang, Zhi-peng
    Liu, Ming
    Wang, Jian-ye
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [39] Neoadjuvant Treatment of High-Risk, Clinically Localized Prostate Cancer Prior to Radical Prostatectomy
    Pietzak, Eugene J.
    Eastham, James A.
    CURRENT UROLOGY REPORTS, 2016, 17 (05)
  • [40] Neoadjuvant Treatment of High-Risk, Clinically Localized Prostate Cancer Prior to Radical Prostatectomy
    Eugene J. Pietzak
    James A. Eastham
    Current Urology Reports, 2016, 17
12345